Adaptimmune TherapeuticsADAP
Market Cap: $279M
About: Adaptimmune Therapeutics PLC is a clinical-stage biopharmaceutical company. It focused on providing novel cell therapies to patients, particularly in solid tumors. It has developed a comprehensive proprietary platform that enables it to identify cancer targets, find and genetically engineer T-cell receptors, and produce TCR therapeutic candidates for administration to patients. Its programs include MAGE-A4 SPEAR T-cell therapy, NY-ESO SPEAR T-cell, CD70 and others for multiple cancer types.
Employees: 449
Fund manager confidence
Based on 2024 Q2 SEC filings by fund managers ($100M+ AUM)
277% more call options, than puts
Call options by funds: $132K | Put options by funds: $35K
0% more funds holding in top 10
Funds holding in top 10: 1 [Q1] → 1 (+0) [Q2]
0.93% less ownership
Funds ownership: 10.97% [Q1] → 10.04% (-0.93%) [Q2]
5% less funds holding
Funds holding: 80 [Q1] → 76 (-4) [Q2]
27% less repeat investments, than reductions
Existing positions increased: 16 | Existing positions reduced: 22
36% less first-time investments, than exits
New positions opened: 7 | Existing positions closed: 11
42% less capital invested
Capital invested by funds: $257M [Q1] → $150M (-$107M) [Q2]
Research analyst outlook
3 Wall Street Analysts provided 1 year price targets over the past 3 months
3 analyst ratings
HC Wainwright & Co. Arthur He 35% 1-year accuracy 11 / 31 met price target | 267%upside $4 | Buy Reiterated | 13 Aug 2024 |
HC Wainwright & Co. Arthur He 35% 1-year accuracy 11 / 31 met price target | 267%upside $4 | Buy Reiterated | 5 Aug 2024 |
HC Wainwright & Co. Arthur He 35% 1-year accuracy 11 / 31 met price target | 267%upside $4 | Buy Initiated | 30 Jul 2024 |
Financial journalist opinion
Based on 3 articles about ADAP published over the past 30 days